´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (3ÀÏÂ÷) : 2022-05-28±³À°ÀÏÀÚ : 2022-05-28
±³À°Àå¼Ò : ¼¿ï µå·¡°ï½ÃƼȣÅÚ
±³À°ÁÖÁ¦ :
KSN(Korea Society of Nephrology) 2022 (3ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ :
ksn@ksn.or.kr ±³À°Á¾·ù : ³»°úÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 31 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í ¡áȸ¿ø: »çÀü(100,000)/ÇöÀå(150,000) ¡áºñȸ¿ø: »çÀü(150,000)/ ÇöÀå(200,000) ¡áFellow-in-training,Resident,Trainee,Student,Nurse,etc: »çÀü(50,000)/ ÇöÀå(35,000) *Medical Student: ¸éÁ¦
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-28 Room 1(5F) 08:30~09:00 Uptodate Review of the Management of Diabetes in Hemodialysis Patients °íÀº½Ç(¿©Àǵµ¼º¸ðº´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 09:00~09:30 Uptodate Review of Intradialytic Hypotension - Mechanism, Clinical Impacts and Management ¹Ú¿ì¿µ(°è¸íÀÇ´ë ½ÅÀå³»°ú)
±³À°½Ã°£ 05-28 Room 1(5F) 09:30~10:00 Uptodate Review of Restless Legs Syndrome - Mechanism, Clinical Impacts and Management ±æÈ¿¿í(õ¾È¼øõÇ⺴¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 10:00~10:30 Uptodate Review of Antithrombotic Therapy for Hemodialysis Patients With Atrial Fibrillation ¼Û¿µ¸²(ÇѸ²´ëÇб³¼º½Éº´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 10:40~11:10 Impact of Sarcopenia on Mortality in Patients Undergoing Hemodialysis ÁöÁ¾Çö(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 11:10~11:40 National Quality Control of Hemodialysis in Korea; A Small Carrot and a Big Stick ±Ç¼ø±æ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 05-28 Room 1(5F) 11:40~12:10 Effect of Dialysis Modality on Chronic Inflammation and Oxidative Stress in Maintenance Hemodialysis Patients Minoru Satoh(Japan Organization of Occupational Health and Safety Kobe Rosai Hospital)
±³À°½Ã°£ 05-28 Room 1(5F) 12:10~12:40 Japanese Reimbursement System for Hemodialysis and Online Hemodiafiltration Yoshihiro Ota(Nagoya Memorial Hospital)
±³À°½Ã°£ 05-28 Room 1(5F) 15:00~15:30 How to Assess Volume Status in Critically Ill Patients ÀÓ¼ºÀ±(ºÐ´ç¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 15:30~16:00 Fluid Versus Vasopressor Therapy in Resuscitation ¿©ÇýÁÖ(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 16:00~16:30 Electrolyte Disturbances in the Neuro Intensive Care Unit ÀÌÁ¤È¯(¼¿ïƯº°½Ãº¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 16:30~17:00 Approaches to Acid-base Disorders: Traditional Versus Stewart Á¤¼ºÁø(¿©Àǵµ°¡Å縯¼º¸ðº´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 17:10~17:40 What Is Aging?; Is Aging a Natural Condition or a Disease? Hidenori Arai(National Center for Geriatrics and Gerontology)
±³À°½Ã°£ 05-28 Room 1(5F) 17:40~18:10 Aging and Kidney Disease ±è¼¸°(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 18:10~18:40 Aging Interventions and Therapies ±ÇÀº¼ö(Çѱ¹»ý¸í°øÇבּ¸¿ø)
±³À°½Ã°£ 05-28 Room 1(5F) 18:40~19:10 Medical Service for Healthy Aging Reshma A. Merchant(National University Hospital)
±³À°½Ã°£ 05-28 Room 2(3F) 08:30~09:00 Kidney Disease Improving Global Outcomes Recommendations for Home Dialysis Martin Wilkie(Sheffield Kidney Institute)
±³À°½Ã°£ 05-28 Room 2(3F) 09:00~09:30 Peritoneal Dialysis Outcomes and Practice Patterns Study Korea and Global ¿À±¹È¯(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-28 Room 2(3F) 09:30~10:00 Incremental Peritoneal Dialysis ¾È¿ø¼®(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05-28 Room 2(3F) 10:00~10:30 Malnutrition in Peritoneal Dialysis °¼®ÈÖ(¿µ³²´ëÇб³ÀÇ·á¿ø)
±³À°½Ã°£ 05-28 Room 2(3F) 10:40~11:10 Overview of Thrombotic Microangiopathy Including COVID-19 ±èÁø¼®(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-28 Room 2(3F) 11:10~11:40 Cytopathology in Shigatoxigenic and verotoxigenic Escherichia coli/enterohemorrhagic E. coli-Hemolytic–uremic syndrome Á¶¸íÇö(ÇѸ²´ëÇб³¼º½Éº´¿ø)
±³À°½Ã°£ 05-28 Room 2(3F) 11:40~12:10 Complementopathy in Atypical Hemolytic–uremic syndrome/C3 Glomerulopathy ±è¸í±Ô(°í·Á´ëÇб³¾È¾Ïº´¿ø)
±³À°½Ã°£ 05-28 Room 2(3F) 12:10~12:40 Clinical Use of Eculizumab and Ravulizumab Fadi Fakhouri(Nantes University Hospital Center)
±³À°½Ã°£ 05-28 Room 2(3F) 15:00~15:30 Optimizing the Corticosteroid Dose in Steroid-sensitive Nephrotic Syndrome Martin Christian(Nottingham University Hospital)
±³À°½Ã°£ 05-28 Room 2(3F) 15:30~16:00 Nephrotic Syndrome Requiring Other than Steroid; Coenzyme Q10 Nephropathy ¹ÚÀ¯Áø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-28 Room 2(3F) 16:00~16:30 What We Learned from Nephrotic Syndrome Registry Studies and Its Implication for Treatment Susan Samuel(University of Calgary)
±³À°½Ã°£ 05-28 Room 2(3F) 16:30~17:00 Childhood-nephrotic Syndrome in Adult Patients ¼Áø¼ø(ºÎõ°¡Å縯¼º¸ðº´¿ø)
±³À°½Ã°£ 05-28 Room 2(3F) 17:10~17:40 The Key Advances in the Pathogenesis of Immunoglobulin A Nephropathy Jonathan Barratt(University of Leicester)
±³À°½Ã°£ 05-28 Room 2(3F) 17:40~18:10 The Key Updates in the 2021 Kidney Disease Improvement Global Outcome Guideline for Immunoglobulin A Nephropathy and New Therapies in for IgA Nephropathy Hong Zhang(Peking University First Hospital)
±³À°½Ã°£ 05-28 Room 2(3F) 18:10~18:40 Beyond Mycophenolate and Cyclophosphamide for Lupus Nephritis ¼Ã¢Èñ(¾ÆÁÖ´ëÇб³º´¿ø)
±³À°½Ã°£ 05-28 Room 2(3F) 18:40~19:10 New Pathophysiology and Clinical Approach in Tubulointerstitial Nephritis Çѽ¼®(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-28 Room 2+3+4(3F) 14:00~14:50 Oxygen Biology in the Kidney Masaomi Nangaku(The University of Tokyo Graduate School of Medicine)
±³À°½Ã°£ 05-28 Room 3(3F) 08:30~09:00 High Protein Diet-Induced Glomerular Hyperfiltration °í°Áö(°í·ÁÀǴ뱸·Îº´¿ø)
±³À°½Ã°£ 05-28 Room 3(3F) 09:00~09:30 Clinical Dilemmas in Heart Failure and Chronic Kidney Disease Management Sunita Bavanandan(Hospital Kuala Lumpur)
±³À°½Ã°£ 05-28 Room 3(3F) 09:30~10:00 Transform, Optimization of Animal Studies to Develop New Drugs Masaomi Nangaku(The University of Tokyo Graduate School of Medicine)
±³À°½Ã°£ 05-28 Room 3(3F) 10:00~10:30 Single Cell Research Update in Kidney Disease ¹ÚÁöȯ(±¤ÁÖ°úÇбâ¼ú¿ø)
±³À°½Ã°£ 05-28 Room 3(3F) 10:40~11:10 A Long Journey for Acute Kidney Injury Biomarkers ½ÅÁ¤È£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 05-28 Room 3(3F) 11:10~11:40 Using Computer Science to Assist Acute Kidney Injury Care - From E-alert to Artificial Intelligence Chih-Hsiang Chang(Chang Gung Memorial Hospital)
±³À°½Ã°£ 05-28 Room 3(3F) 11:40~12:10 Prevention and Treatment of Acute Kidney Injury From the Viewpoint of Renal Congestion Masanori Abe(Nihon University)
±³À°½Ã°£ 05-28 Room 3(3F) 12:10~12:40 Therapeutic Exosomes for Acute Kidney Injury ±è¼ºÈÆ(¿¬¼¼´ëÇб³ Ä¡ÀÇ°ú´ë)
±³À°½Ã°£ 05-28 Room 3(3F) 15:00~15:30 Clinical Consideration in Using Sodium-Glucose Linked Transporter-2 Inhibitors Meg Jardine(University of Sydney)
±³À°½Ã°£ 05-28 Room 3(3F) 15:30~16:00 Clinical Consideration in Using MRAs ±è¿¹¸²(°è¸íÀÇ´ë)
±³À°½Ã°£ 05-28 Room 3(3F) 16:00~16:30 Pleotropic Effects of HIF-PHIs, Are There Clinical Relevant Yu-Hsiang Chou (National Taiwan University)
±³À°½Ã°£ 05-28 Room 3(3F) 16:30~17:00 Renoprotective Effect of ET Inhibitor ¿À¼¼¿ø(°í·Á´ëÇб³¾È¾Ïº´¿ø)
±³À°½Ã°£ 05-28 Room 3(3F) 17:10~17:40 Advances in Immunoglobulin A Nephropathy ¿ÀÅ·Å(Àü³²´ëÇб³º´¿ø)
±³À°½Ã°£ 05-28 Room 3(3F) 17:40~18:10 Advances in Membranous Nephropathy Vivek Jha(The George Institute for Global Health)
±³À°½Ã°£ 05-28 Room 3(3F) 18:10~18:40 Advances in atypical Hemolytic Uremic Syndrome /Thrombotic Microangiopathy °ÀºÁ¤(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 05-28 Room 3(3F) 18:40~19:10 Advances in Lupus Nephritis Kah Mean Thong(Hospital Ipoh)
±³À°½Ã°£ 05-28 Room 4(3F) 08:30~08:40 Gut Microbial Genes and Metabolism for Methionine and Branched-Chain Amino Acids in Diabetic Nephropathy ±èÁöÀº(°í·ÁÀǴ뱸·Îº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 08:40~08:50 Non-invasive Biomarker Using Urinary Exosome miRNA That Reflects Pathologic Features of Patients With Diabetic Kidney Diseases ±è´ë±Ô(°µ¿°æÈñ´ëº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 08:50~09:00 Curcumin Blocks High Glucose-Induced Podocyte Injury via Receptor-interacting serine/threonine-protein kinase 3 -Dependent Pathway À̼º¿ì(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-28 Room 4(3F) 09:00~09:10 Periostin Deficiency Attenuates Kidney Fibrosis and Pancreatic ¥â-Cell Dysfunction Though Reducing Tenascin C Under Diabetic Conditions Á¶¾Æ¶ó(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-28 Room 4(3F) 09:10~09:20 Effects of Zinc Oxide Nanoparticles on Oxidative Stress and Renal Function in Fat-Fed and Streptozotocin-Treated Rats Pardeep Kumar(F H M College and Hospital)
±³À°½Ã°£ 05-28 Room 4(3F) 09:20~09:30 Similar Risk of Kidney Function Decline Between Tenofovir Alafenamide and Besifovir Dipivoxil Maleate in Chronic Hepatitis B Á¤Âù¿µ(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 09:30~09:40 Urinary Sodium-To-Potassium Ratio and Chronic Kidney Disease Progression in Non-dialysis-Dependent Chronic Kidney Disease Patients: Results From the KNOW-Chronic Kidney Disease Study °µ¿Çõ(°í·ÁÀǴ뱸·Îº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 09:40~09:50 Long-Term Exposure to High Perceived Temperature and Risk for Mortality Among Chronic Kidney Disease Patients ÀÌÁ¤È¯(¼¿ïƯº°½Ãº¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 09:50~10:00 SGLT2 Inhibitor Reduces Urinary Mitochondrial DNA in Chronic Kidney Disease Patients With or Without Type 2 Diabetes Mellitus ÀÌÇØ°æ(¼øõÇâ´ëÇб³º´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 10:00~10:10 Age-Specific Estimated Glomerular Filtration Rate and Outcomes: Insights From the KNOW-Chronic Kidney Disease Cohort ±èÁöÇý(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 10:10~10:20 Development and Validation of Deep Learning Algorithm for Evaluating Kidney Function Based on Electrocardiogram ¾ÈÁ¤³²(ÇѸ²´ëÇб³¼º½Éº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 10:20~10:30 Rosuvastatin Inhibits Tubulointerstitial Fibrosis via Activating HOX13-BMP-7 Pathway ¿Àµ¿È¯(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 10:40~11:10 Artificial intelligence Application in Renal Pathology °íÇöÁ¤(¿ï»êÀÇ´ë ¾Æ»êº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 11:10~11:40 Expert-Level Segmentation Using Deep Learning for Volumetry of Autosomal Dominant Polycystic Kidney Disease ¹è°æÅÂ(University of Pittsburgh)
±³À°½Ã°£ 05-28 Room 4(3F) 11:40~12:10 Building Risk Prediction Models in Acute Kidney Injury ¹ÎÁö¿ø(ºÎõ°¡Å縯¼º¸ðº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 12:10~12:40 AI Application to Improve Hemodialysis Adequacy ±èÇü¿ì(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 15:00~15:30 The Evolution of Evidence Generation in Chronic Kidney Disease-Anemia: A History of Agents and Trial Designs Wolfgang Winkelmayer(Baylor College of Medicine)
±³À°½Ã°£ 05-28 Room 4(3F) 15:30~16:00 Anemia in Chronic Kidney Disease Patients: Result From the Know-Chronic Kidney Disease ¿À±¹È¯(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 16:00~16:30 HIF-PHI Trials in Chronic Kidney Disease Non-dialysis and Dialysis: What Do the Data Really Show? David Wheeler(University College London)
±³À°½Ã°£ 05-28 Room 4(3F) 16:30~17:00 Appropriate use of Hypoxia-Inducible Factor Prolyl Hydroxylase inhibitor in Korean with Chronic Kidney Disease ±è¼º±Õ(ÇѸ²´ëÇб³¼º½Éº´¿ø)
±³À°½Ã°£ 05-28 Room 4(3F) 17:00~17:30 The Evolving Roles of Iron Treatment, ESAs, and Hypoxia-inducible factor prolyl hydroxylase Inhibitors Towards Successful Anemia Treatment Elain Ku(University of California , San Francisco)
±³À°½Ã°£ 05-28 Room 4(3F) 17:30~18:00 Treatment of Anemia:Beyond Erythropoietin in Korea 2022 ÁöÁ¾Çö(°³²¼¼ºê¶õ½ºº´¿ø)